Todas las noticias

Spineway Group, specialists in innovative implants for the treatment of severe spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spine implant industry at the North American Spine Society (NASS) Congress in Los Angeles last October1.

Spineway Group, a specialist in innovative implants for the treatment of severe spinal conditions, is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.

Spineway recorded revenue of €2.1 million in the third quarter of 2023, taking the 9-month total to €7.5 million, a 40% increase compared with 2022. Revenue growth over the first 9 months was driven mainly by sales by Spine Innovations, consolidated in July 2022. As announced, third-quarter revenue was automatically impacted by a less favorable impact from change in scope.

The Board of Directors of Spineway, meeting on September 18, 2023, under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, 2023.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO1(Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held on September 9 in Behoust (France) and focused on total disc replacement using prostheses.

Spineway’s total revenue for the first half of 2023 was €5.4 million, up 75% compared with the first half of 2022. Growth was driven mainly by the contribution of sales of Spine Innovations, acquired in July 2022. However, organic growth1 remained sustained, representing 12% in the first half of 2023, thanks to the steep increase in Distimp sales (+66%), demonstrating the momentum spurred by the Group’s commercial activity over the period.

Spineway, a specialist in innovative implants for the treatment of severe disorders of the spinal column, has been on a new growth trajectory for more than a year, driven by the acquisitions of Distimp in June 2021 and Spine Innovations in July 2022. These acquisitions have enabled it to extend its geographical footprint, to offer two operating techniques – fusion and non-fusion – and to stimulate product innovation

Spineway has achieved a total revenue of €2.4 million as of Q1 2023, representing growth of 79% compared with Q1 2022, mainly driven by sales of Spine Innovations’ disc prostheses. Adjusted for this contribution, quarterly revenue remainsrobust and represents an all-time high of €1.4 million despite a temporary delay in Latin America due to regulatory procedures for the approval of new products.

The Ordinary and Extraordinary General Meeting of Spineway's shareholders was held on first call on Tuesday, April 4, 2023 at 11:00 a.m. at the Group's registered office, 7 allée Moulin Berger in Ecully (69)